Latest Inhaler Stories

2011-07-28 10:00:00

LOS ANGELES, July 28, 2011 /PRNewswire/ -- UBM Canon has announced that it will produce the Pharmapack North America conference and exhibition May 22-23, 2012 in Philadelphia's PA Convention Center. The technology-focused conference and exhibition, which focuses upon innovation in packaging technology and drug delivery systems to enhance health product safety, is the counterpart of the company's highly successful show in Paris, France. (Logo:...

2011-07-26 08:00:00

CANTON, Mass., July 26, 2011 /PRNewswire/ -- Armstrong Pharmaceuticals, Inc. announced the following news today concerning the future availability of Primatene® Mist: On December 31, 2011, the FDA ban on the sale of Primatene® Mist containing CFCs (chlorofluorocarbons) as a propellant will become effective. Primatene® Mist has proven to be a safe and effective treatment for asthma symptoms for over 40 years. The ban on the sale of...

2011-06-17 06:37:04

(Ivanhoe Newswire) -- People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, according to this study. The findings raise concerns not only about the mist inhaler- a device that delivers a soluble form of the medication tiotropium- but also about the drug itself. The mist inhaler isn't approved in the U.S., but the drug in its powdered form is commonly used to treat...

2011-06-16 08:00:00

REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD. PT003 (GFF MDI) is an investigational inhaled combination bronchodilator product comprising glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA), and formoterol (FF), a well-known, established,...

2011-06-16 05:35:00

According to new study, Respimat, a mist inhaler that delivers a widely-prescribed respiratory drug, increases the risk of dying by half. The British and U.S. researchers looked at five trials involving Respimat, which can be alternatively taken in powder form. The drug Respimat uses tiotropium bromide, which relaxes muscles in the airways.  It is designed to ease symptoms of chronic obstructive respiratory disease (COPD), the world's fourth leading cause of death. The study was an...

2011-06-15 13:37:55

People who use a mist inhaler to deliver a drug widely prescribed in more than 55 countries to treat chronic obstructive pulmonary disease (COPD) may be 52 percent more likely to die, new Johns Hopkins-led research suggests. The findings, published by BMJ, the British Medical Journal, raise concerns not only about the mist inhaler "” a device that delivers the soluble form of the medication tiotropium "” but also about the drug itself. The mist inhaler has not yet gained...

2011-06-14 12:41:00

LISBON, Portugal, June 14, 2011 /PRNewswire/ -- Hovione announced today the international filing of its latest patent covering a new, highly efficient dry powder inhaler (DPI), XCaps. XCaps fills a void in the pulmonary inhalation market, as a device which combines high efficiency in powder dispersion with ease of use. Lung fractions in excess of 70% have been achieved, from a device which only requires two steps to inhalation and which only has two components plus a dust...

Word of the Day
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'